<h4>Background</h4>Thrombopoietin receptor agonists (TPO-RA) are widely used for immune thrombocytopenia (ITP), but their post-marketing thromboembolic safety profiles and onset patterns remain incompletely characterized.<h4>Methods</h4>FAERS reports from January 2009 to December 2024 were cleaned to remove duplicates and non-suspected roles, yielding 2,092 unique thromboembolic AE cases. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.